Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 16, 2022

SELL
$7.31 - $11.85 $803,668 - $1.3 Million
-109,941 Closed
0 $0
Q1 2022

May 17, 2022

BUY
$7.35 - $10.63 $630,600 - $912,011
85,796 Added 355.34%
109,941 $904,000
Q4 2021

Feb 15, 2022

BUY
$4.19 - $9.56 $101,167 - $230,826
24,145 New
24,145 $231,000
Q2 2021

Aug 16, 2021

SELL
$3.95 - $5.41 $67,584 - $92,565
-17,110 Closed
0 $0
Q1 2021

May 18, 2021

SELL
$4.52 - $7.8 $1,148 - $1,981
-254 Reduced 1.46%
17,110 $91,000
Q4 2020

Feb 17, 2021

BUY
$4.37 - $9.46 $75,880 - $164,263
17,364 New
17,364 $122,000

Others Institutions Holding TCDA

About Tricida, Inc.


  • Ticker TCDA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,668,900
  • Market Cap $557K
  • Description
  • Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...
More about TCDA
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.